Kenneth Kern

SchoolVc-academic Affairs
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2023 03; 11(3). Autio KA, Higano CS, Nordquist L, Appleman LJ, Zhang T, Zhu XH, Babiker H, Vogelzang NJ, Prasad SM, Schweizer MT, Madan RA, Billotte S, Cavazos N, Bogg O, Li R, Chan K, Cho H, Kaneda M, Wang IM, Zheng J, Tang SY, Hollingsworth R, Kern KA, Petrylak DP. PMID: 36948505; PMCID: PMC10040068.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    2. Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. Br J Cancer. 2023 Jan; 128(2):400. Curigliano G, Shapiro GI, Kristeleit RS, Abdul Razak AR, Leong S, Alsina M, Giordano A, Gelmon KA, Stringer-Reasor E, Vaishampayan UN, Middleton M, Olszanski AJ, Rugo HS, Kern KA, Pathan N, Perea R, Pierce KJ, Mutka SC, Wainberg ZA. PMID: 36697966; PMCID: PMC9902525.
      View in: PubMed   Mentions:    Fields:    
    3. A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. Br J Cancer. 2023 01; 128(1):30-41. Curigliano G, Shapiro GI, Kristeleit RS, Abdul Razak AR, Leong S, Alsina M, Giordano A, Gelmon KA, Stringer-Reasor E, Vaishampayan UN, Middleton M, Olszanski AJ, Rugo HS, Kern KA, Pathan N, Perea R, Pierce KJ, Mutka SC, Wainberg ZA. PMID: 36335217; PMCID: PMC9814742.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    4. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Target Oncol. 2017 Dec; 12(6):775-785. Wainberg ZA, Alsina M, Soares HP, Braña I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero J. PMID: 29067643; PMCID: PMC5700209.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    5. Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer. Oncotarget. 2017 Jan 10; 8(2):2320-2328. Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, Curigliano G. PMID: 27906684; PMCID: PMC5356802.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    6. Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology. J Oncol Pract. 2016 08; 12(8):e810-7. Kern KA. PMID: 27460496.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    7. PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib. Clin Pharmacol Drug Dev. 2015 03; 4(2):89-98. Wang DD, Li C, Sun W, Zhang S, Shalinsky DR, Kern KA, Curtin NJ, Sam WJ, Kirkpatrick TR, Plummer R. PMID: 27128213.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    8. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014. Clin Cancer Res. 2015 Jan 01; 21(1):60-7. Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM. PMID: 25231399.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansCTClinical Trials
    9. Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer. 2014 Mar 07; 14:166. Bachelot T, Garcia-Saenz JA, Verma S, Gutierrez M, Pivot X, Kozloff MF, Prady C, Huang X, Khosravan R, Wang Z, Cesari R, Tassell V, Kern KA, Blay JY, Lluch A. PMID: 24606768; PMCID: PMC3995914.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    10. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast. 2013 Oct; 22(5):650-6. Curigliano G, Pivot X, Cortés J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A. PMID: 23958375.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    11. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol. 2013 Aug 10; 31(23):2870-8. Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, Greil R, Cognetti F, Fountzilas G, Blasinska-Morawiec M, Liedtke C, Kreienberg R, Miller WH, Tassell V, Huang X, Paolini J, Kern KA, Romieu G. PMID: 23857972.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    12. Phase II open-label study of sunitinib in patients with advanced breast cancer. Breast Cancer Res Treat. 2012 Dec; 136(3):759-67. Yardley DA, Dees EC, Myers SD, Li S, Healey P, Wang Z, Brickman MJ, Paolini J, Kern KA, Citrin DL. PMID: 23073758.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    13. An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. Breast. 2012 Dec; 21(6):716-23. Cardoso F, Canon JL, Amadori D, Aldrighetti D, Machiels JP, Bouko Y, Verkh L, Usari T, Kern KA, Giorgetti C, Dirix L. PMID: 23022045.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    14. Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib. J Transl Med. 2012 Aug 16; 10:165. Keyvanjah K, DePrimo SE, Harmon CS, Huang X, Kern KA, Carley W. PMID: 22897944; PMCID: PMC3499375.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    15. Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast. 2012 Aug; 21(4):507-13. Bergh J, Mariani G, Cardoso F, Liljegren A, Awada A, Viganò L, Huang X, Verkh L, Kern KA, Giorgetti C, Gianni L. PMID: 22336056.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    16. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol. 2012 Mar 20; 30(9):921-9. Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C. PMID: 22331954.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCTClinical Trials
    17. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer. 2011 Apr; 11(2):82-92. Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, Brufsky AM, Minton SE, Giguere JK, Smith JW, Richards PD, Gernhardt D, Huang X, Liau KF, Kern KA, Davis J. PMID: 21569994; PMCID: PMC4617186.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    18. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010 May; 121(1):121-31. Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M. PMID: 20339913; PMCID: PMC2855860.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCTClinical Trials
    19. Achieving the lowest false-negative rate in peritumoral breast lymphatic mapping: the oncologic search for the Holy Grail. Ann Surg Oncol. 2003 Jun; 10(5):486-7. Kern KA. PMID: 12794011.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. When medical error becomes medical malpractice: the victims and the circumstances. Arch Surg. 2003 Apr; 138(4):447-54. Tracy TF, Crawford LS, Krizek TJ, Kern KA. PMID: 12686532.
      View in: PubMed   Mentions: 1     Fields:    
    21. Concordance and validation study of sentinel lymph node biopsy for breast cancer using subareolar injection of blue dye and technetium 99m sulfur colloid. J Am Coll Surg. 2002 Oct; 195(4):467-75. Kern KA. PMID: 12375751.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    22. A rational approach to internal mammary node biopsy in the era of lymphatic mapping for breast cancer. J Surg Oncol. 2002 Jan; 79(1):5-9. Kern KA. PMID: 11754371.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Kenneth's Networks
    Concepts (106)
    Derived automatically from this person's publications.
    Co-Authors (2)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department